You are viewing the site in preview mode
Skip to main content
| Age | 32 years (17–60) |
| Age of onset | 18 years (3–46) |
| Sex |
| Female | n: 32 | 49.2% |
| Male | n: 33 | 50.8% |
| Duration of use | n: 65 (100%) | 7 month (3–30) |
| Anakinra | n: 41 (63.1%) | 6 month (3–30) |
| Canakinumab | n: 24 (39.6%) | 8 month (3–25) |
| Clinical Features |
| Fever | n: 60 | 92.5% |
| Peritonitis | n: 61 | 93.8% |
| Erysipales LE | n: 18 | 27.7% |
| Amlyloidosis | n: 15 | 23.1% |
| Arthritis | n: 11 | 16.9% |
| Pleuritis | n: 20 | 30.8% |
| AxSpa | n: 9 | 13.8% |
| Renal trans | n: 7 | 10.8% |
| MEFV Mutation |
| M694 V homozygous | n: 29 | 44.6% |
| M694 V heterozygous | n: 8 | 12.3% |
| M680I homozygous | n: 4 | 6.2% |
| E148Q homozygous | n: 1 | 1.5% |
| Compound | n: 16 | 24.6% |
| No | n: 3 | 4.6% |
| R761H heterozygous | n: 1 | 1.5% |
| Others | n: 3 | 4.6% |
| Indications of Anti-IL1 therapy |
| Colchicine-Intolerant | n: 8 | 12.3% |
| Colchicine-Resistant | n: 46 | 70.8% |
| Proteinuria | n: 15 | 23.1% |
- All parameters are presented as median (min–max) or number (%). LE like erythema, AxSpa axialspondyloarthropathy
